Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GYRE THERAPEUTICS, INC.CBIO · Entity 5247 | Chief Medical Officer | August 09, 2021 | August 11, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GYRE THERAPEUTICS, INC.
Report date August 09, 2021 · Filed August 11, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 639 |
Reported balance
After 2021-08-09 transaction · row 1
1 source rowRow 1 · 2021-08-09 · Purchase · Acquired 639 · Balance 639 F1: Shares purchased under the Issuer's 2018 Employee Stock Purchase Plan on August 9, 2021. |
| Common StockSEC Table I · non-derivative | IndirectBy Howard and Gillian Levy Revocable Trust dated November 21, 1994 | 23,390 |
Reported balance
Holding disclosure · report date 2021-08-09 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 23,390 |
Filing footnotes · ownership attribution and instrument terms
F1: Shares purchased under the Issuer's 2018 Employee Stock Purchase Plan on August 9, 2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 09, 2021 Filed Aug 11, 2021 13:14 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | PurchaseCommon Stock | 639 | $3.62 | $2,313.18 |
DisclosureSEC source: 0001209191-21-050758 · doc4.xml · nonDerivative · entry 1 Levy Howard · CIK 0001672333 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 639 F1 · shares: Shares purchased under the Issuer's 2018 Employee Stock Purchase Plan on August 9, 2021. Read SEC document |
| February 09, 2021 Filed Feb 23, 2021 02:33 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | PurchaseCommon Stock | 1,670 | $4.81 | $8,032.70 |
DisclosureSEC source: 0001209191-21-013036 · doc4.xml · nonDerivative · entry 1 Levy Howard · CIK 0001672333 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Howard and Gillian Levy Revocable Trust dated November 21, 1994 Disclosed balance after: 23,390 F1 · shares: Shares purchased under the Issuer's 2018 Employee Stock Purchase Plan on February 9, 2021. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 22:50 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $5.89 | $0.00 |
DisclosureSEC source: 0001209191-21-009347 · doc4.xml · derivative · entry 1 Levy Howard · CIK 0001672333 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-02-08 F1 · derivative.exercise_date: Award vests over a four (4) year period on each monthly anniversary commencing February 8, 2021. Read SEC document |
| February 08, 2021 Filed Apr 26, 2021 21:38 UTC Amendment | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $5.89 | $0.00 |
DisclosureSEC source: 0001209191-21-028355 · doc4a.xml · derivative · entry 1 Levy Howard · CIK 0001672333 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-02-08 F1 · derivative.exercise_date: Award vests and will become exercisable monthly over 48 months, with 25% of the shares vesting on the 12-month anniversary of the date hereof, and the remainder vesting monthly thereafter at the rate of 1/48th of the total number of shares. Read SEC document |
| August 10, 2020 Filed Aug 12, 2020 20:11 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | PurchaseCommon Stock | 1,768 | $4.81 | $8,504.08 |
DisclosureSEC source: 0001209191-20-046347 · doc4.xml · nonDerivative · entry 1 Levy Howard · CIK 0001672333 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,268 F1 · shares: Shares purchased under the Issuer's 2018 Employee Stock Purchase Plan on August 10, 2020. Read SEC document |
| March 16, 2020 Filed Mar 17, 2020 20:23 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | PurchaseCommon Stock | 2,500 | $4.05 | $10,131.50 |
DisclosureSEC source: 0001209191-20-019584 · doc4.xml · nonDerivative · entry 1 Levy Howard · CIK 0001672333 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Read SEC document |
| February 10, 2020 Filed Feb 13, 2020 01:28 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 1,358 | $6.23 | $8,460.34 |
DisclosureSEC source: 0001209191-20-009040 · doc4.xml · nonDerivative · entry 1 Levy Howard · CIK 0001672333 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,358 F1 · shares: Shares purchased under the Catalyst Biosciences, Inc. 2018 Employee Stock Purchase Plan ("ESPP") on February 10, 2020. Read SEC document |
| January 23, 2020 Filed Jan 27, 2020 19:00 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $6.85 | $0.00 |
DisclosureSEC source: 0001209191-20-004966 · doc4.xml · derivative · entry 1 Levy Howard · CIK 0001672333 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2030-01-23 F1 · derivative.exercise_date: Award vests over a four (4) year period on each monthly anniversary commencing January 23, 2020. Read SEC document |
| May 21, 2019 Filed May 22, 2019 16:23 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GiftCommon Stock | 16,094 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-031947 · doc4.xml · nonDerivative · entry 2 Levy Howard · CIK 0001672333 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Howard and Gillian Levy Revocable Trust dated November 21, 1994 Disclosed balance after: 16,094 F1 · balance_after: On May 21, 2019, the reporting person transferred 16,094 directly owned shares of Company common stock to the Howard and Gillian Levy Revocable Trust dated November 21, 1994, of which the insider and his wife are trustees and beneficiaries. Read SEC document |
| May 21, 2019 Filed May 22, 2019 16:23 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | Exercise / conversionCommon Stock | 4,400 | $4.63 | $20,372.00 |
DisclosureSEC source: 0001209191-19-031947 · doc4.xml · nonDerivative · entry 1 Levy Howard · CIK 0001672333 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,094 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 20, 2019 Filed May 22, 2019 16:23 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,400 | $0.00 Strike: $4.63 | $0.00 |
DisclosureSEC source: 0001209191-19-031947 · doc4.xml · derivative · entry 3 Levy Howard · CIK 0001672333 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,218 Underlying: Common Stock · 4,400 shares Expires 2027-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The Option vests monthly over a period of four years commencing June 15, 2017. Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 22:00 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 2,485 | $7.04 | $17,494.40 |
DisclosureSEC source: 0001209191-19-009704 · doc4.xml · nonDerivative · entry 1 Levy Howard · CIK 0001672333 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,867 F1 · shares: Shares purchased under the Catalyst Biosciences, Inc. 2018 Employee Stock Purchase Plan ("ESPP") on February 11, 2019. Read SEC document |
| January 31, 2019 Filed Feb 4, 2019 21:53 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,500 | $0.00 Strike: $4.63 | $0.00 |
DisclosureSEC source: 0001209191-19-006862 · doc4.xml · derivative · entry 2 Levy Howard · CIK 0001672333 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,500 Underlying: Common Stock · 1,500 shares Expires 2027-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Option vests monthly over a period of four years commencing June 15, 2017. Read SEC document |
| January 31, 2019 Filed Feb 4, 2019 21:53 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | Exercise / conversionCommon Stock | 1,500 | $4.63 | $6,945.00 |
DisclosureSEC source: 0001209191-19-006862 · doc4.xml · nonDerivative · entry 1 Levy Howard · CIK 0001672333 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,382 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 24, 2019 Filed Jan 28, 2019 23:54 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $7.97 | $0.00 |
DisclosureSEC source: 0001209191-19-005666 · doc4.xml · derivative · entry 1 Levy Howard · CIK 0001672333 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2029-01-24 F1 · derivative.exercise_date: Award vests over a four (4) year period on each monthly anniversary commencing January 24, 2019. Read SEC document |
| November 26, 2018 Filed Nov 27, 2018 22:01 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | Exercise / conversionStock Option (Right to Buy) · Derivative | 149 | $0.00 Strike: $4.63 | $0.00 |
DisclosureSEC source: 0001209191-18-060006 · doc4.xml · derivative · entry 2 Levy Howard · CIK 0001672333 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,118 Underlying: Common Stock · 149 shares Expires 2027-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Option vests monthly over a period of four years commencing June 15, 2017. Read SEC document |
| November 26, 2018 Filed Nov 27, 2018 22:01 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | Exercise / conversionCommon Stock | 149 | $4.63 | $689.87 |
DisclosureSEC source: 0001209191-18-060006 · doc4.xml · nonDerivative · entry 1 Levy Howard · CIK 0001672333 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,709 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 22:56 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | Exercise / conversionStock Option (Right to Buy) · Derivative | 173 | $0.00 Strike: $4.63 | $0.00 |
DisclosureSEC source: 0001209191-18-059044 · doc4.xml · derivative · entry 3 Levy Howard · CIK 0001672333 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,267 Underlying: Common Stock · 173 shares Expires 2027-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The Option vests monthly over a period of four years commencing June 15, 2017. Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 22:56 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | SaleCommon Stock | 173 | $11.00 | $1,903.00 |
DisclosureSEC source: 0001209191-18-059044 · doc4.xml · nonDerivative · entry 2 Levy Howard · CIK 0001672333 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,560 F1 · shares: Sale of shares made pursuant to and in accordance with the requirements of Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, under a plan adopted by the Reporting Person on September 5, 2018. Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 22:56 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | Exercise / conversionCommon Stock | 173 | $4.63 | $800.99 |
DisclosureSEC source: 0001209191-18-059044 · doc4.xml · nonDerivative · entry 1 Levy Howard · CIK 0001672333 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,733 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 30, 2018 Filed Aug 1, 2018 21:47 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $9.68 | $0.00 |
DisclosureSEC source: 0001209191-18-044788 · doc4.xml · derivative · entry 1 Levy Howard · CIK 0001672333 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2028-07-30 F1 · derivative.exercise_date: Award vests monthly over four (4) years starting June 13, 2018. Read SEC document |
| May 03, 2018 Filed May 4, 2018 20:58 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,560 | $0.00 Strike: $4.63 | $0.00 |
DisclosureSEC source: 0001209191-18-028135 · doc4.xml · derivative · entry 2 Levy Howard · CIK 0001672333 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,440 Underlying: Common Stock · 7,560 shares Expires 2027-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Option vests monthly over a period of four years commencing June 15, 2017. F2 · derivative.expiration_date: Due to clerical error, the expiration date of the grant was erroneously reported on the Form 4 filed July 13, 2017 as "07/11/2017". This filing corrects that error. Read SEC document |
| May 03, 2018 Filed May 4, 2018 20:58 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | Exercise / conversionCommon Stock | 7,560 | $4.63 | $35,002.80 |
DisclosureSEC source: 0001209191-18-028135 · doc4.xml · nonDerivative · entry 1 Levy Howard · CIK 0001672333 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,560 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 12, 2018 Filed Jan 16, 2018 20:42 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantStock Option(Right to Buy) · Derivative | 33,000 | $0.00 Strike: $15.13 | $0.00 |
DisclosureSEC source: 0000899243-18-001062 · doc4.xml · derivative · entry 1 Levy Howard · CIK 0001672333 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,000 Underlying: Common Stock · 33,000 shares Expires 2028-01-12 F1 · derivative.exercise_date: The Option vests monthly over a period of four years commencing January 12, 2018. Read SEC document |
| July 11, 2017 Filed Jul 12, 2017 20:48 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 95,000 | $0.00 Strike: $4.63 | $0.00 |
DisclosureSEC source: 0001209191-17-044902 · doc4.xml · derivative · entry 1 Levy Howard · CIK 0001672333 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Stock · 95,000 shares Expires 2017-07-11 F1 · derivative.exercise_date: The Option vests monthly over a period of four years commencing June 15, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.